Search
Avibactam
go.drugbank.com/drugs/DB09060ApprovedInvestigationalinfections, including pyelonephritis caused by antibiotic resistant-pathogens, including those caused by multi-drug resistant gram-negative bacterial pathogens. … This combination was approved by the FDA on February 25, 2015 for the treatment of complicated intra-abdominal infections in combination with metronidazole, and the treatment of complicated urinary tract
Zalcitabine
go.drugbank.com/drugs/DB00943ApprovedWithdrawnA dideoxynucleoside compound in which the 3'-hydroxyl group on the sugar moiety has been replaced by a hydrogen. … The compound is a potent inhibitor of HIV replication at low concentrations, acting as a chain-terminator of viral DNA by binding to reverse transcriptase.
Categories: Antivirals for Systemic Use, Antiinfectives for Systemic UseAnthrax vaccine
go.drugbank.com/drugs/DB11003ApprovedInvestigational[L47561] There are currently 2 anthrax vaccines approved by the FDA: BioThrax in August 15, 2016 and CYFENDUS in July 20, 2023.
Praziquantel
go.drugbank.com/drugs/DB01058ApprovedInvestigationalVet approved[A263201] The efficacy of praziquantel in treating parasitic flatworms infection with low cost (~US$0.20 drug cost to treat a child) makes it an integral to WHO's plan to eliminate schistosomiasis by 2030
Hepatitis B immune globulin
go.drugbank.com/drugs/DB05276ApprovedInvestigationalLong-term hepatitis B immune globulin (HBIG) has been shown to reduce hepatitis B virus (HBV) reinfection in patients transplanted for hepatitis B. Infection with hepatitis B may lead to hepatocellular carcinoma, a type of liver cancer. ...
Categories: Antiinfectives for Systemic UseHuman thrombin
go.drugbank.com/drugs/DB11571ApprovedInvestigationalFurthermore, human thrombin is manufactured by chromatographic purification of prothrombin from cryo-poor plasma followed by activation with calcium chloride [FDA Label]. … Thrombin is a highly specific serine protease encoded by the F2 gene that transforms soluble fibrinogen into insoluble fibrin.
Roflumilast
go.drugbank.com/drugs/DB01656ApprovedInvestigationalThe cream formulation was first approved by the FDA in July 2022 [L42580] and by Health Canada in April 2023. … [L46546] It was first approved by the EMA in July 2010, and by the FDA in January 2018.[L37564] Roflumilast topical cream is indicated to treat plaque psoriasis.
Categories: Antipsoriatics for Topical UseBotulinum toxin type A
go.drugbank.com/drugs/DB00083ApprovedInvestigationalIn 2002, botulinum toxin A, also known as onabotulinumtoxinA or Botox, was the first type A botulism toxin to be introduced into the market for cosmetic use. … [A231819,L32569] A popular use for Botox is the treatment of facial wrinkles and lines, however, there are many uses for the botulinum toxin A in the treatment of dystonia, incontinence, migraine, blepharospasm
Sotorasib
go.drugbank.com/drugs/DB15569ApprovedInvestigational[A187550] Mutant KRAS discovered in 1982 but was not considered a druggable target until the mid-2010s.[A235168] It is the first experimental KRAS inhibitor. … Sotorasib, also known as AMG-510, is an acrylamide-derived KRAS inhibitor developed by Amgen.
Pertuzumab
go.drugbank.com/drugs/DB06366ApprovedInvestigationalIt was first approved by the FDA in 2012 for use with [docetaxel] and another HER2-targeted monoclonal antibody, [trastuzumab], in the treatment of metastatic HER2-positive breast cancer. … Its indicated conditions have since expanded to include use as both a neoadjuvant therapy and an adjuvant therapy in the treatment of HER2-positive breast cancers at high risk of recurrence.